c-myc Oncogene gene dosage, serum CEA and CA-15.3 antigen levels, and cellular DNA values in relation to ex vivo chemosensitivity of primary human breast cancer

被引：7

作者：

Falkiewicz, B ^{[1
]}

Schlotter, CM

Bosse, U

Bielawski, K

Vogt, U

机构：

[1] Univ Gdansk, Fac Biotechnol, Mol Diagnost Div, PL-80952 Gdansk, Poland

[2] Med Univ Gdansk, PL-80952 Gdansk, Poland

[3] Univ Gdansk, Fac Chem, PL-80952 Gdansk, Poland

[4] St Elisabeth Hosp, Dept Obstet Gynecol, Ibbenburen, Germany

[5] Inst Pathol, Osnabruck, Germany

[6] European Lab Assoc, Sect Ibbenburen, Ibbenburen, Germany

来源：

ACTA BIOCHIMICA POLONICA | 2000年 / 47卷 / 01期

关键词：

breast cancer; antitumor drug screening assays; cultured tumor cells; antineoplastic agents; drug resistance; oncogenes;

D O I：

10.18388/abp.2000_4072

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A pilot study on relationships of selected molecular factors (c-myc oncogene average gene copy numbers (AGCN); serum CEA and CA 15.3 antigen levels; tumor cells' DNA values), to the ex vivo chemosensitivity of primary female human breast cancer in a modified adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA), was performed. Four drug combinations were tested. A group of 75 cases of female primary breast cancer was assessed. Numerous correlations were found among molecular factors tested but none, with the exception of tumor grading, of these reflected ex vivo chemosensitivity of tumors tested. The results suggest that the parameters tested may not be important factors related to adjuvant chemoresponsiveness of primary human breast cancer to tested drug combinations.

引用

页码：149 / 156

页数：8

共 31 条

[1] TCA-100 TUMOR CHEMOSENSITIVITY ASSAY - DIFFERENCES IN SENSITIVITY BETWEEN CULTURED TUMOR-CELL LINES AND CLINICAL-STUDIES [J].

ANDREOTTI, PE ;

LINDER, D ;

HARTMANN, DM ;

CREE, IA ;

PAZZAGLI, M ;

BRUCKNER, HW .

JOURNAL OF BIOLUMINESCENCE AND CHEMILUMINESCENCE, 1994, 9 (06) :373-378

[2]

ANDREOTTI PE, 1995, CANCER RES, V55, P5276

[3]

Beckmann A, 1999, CLIN CHEM, V45, P141

[4] ONCOGENE AMPLIFICATION AND PROGNOSIS IN BREAST-CANCER - RELATIONSHIP WITH SYSTEMIC TREATMENT [J].

BERNS, EMJJ ;

FOEKENS, JA ;

VANSTAVEREN, IL ;

VANPUTTEN, WLJ ;

DEKONING, HYWCM ;

PORTENGEN, H ;

KLIJN, JGM .

GENE, 1995, 159 (01) :11-18

[5]

BRANDT B, 1994, METHODS IN DNA AMPLIFICATION, P55

[6] DOUBLE-DIFFERENTIAL PCR FOR GENE DOSAGE ESTIMATION OF ERBB ONCOGENES IN BENIGN AND CANCER TISSUES AND COMPARISON TO CELLULAR DNA CONTENT [J].

BRANDT, B ;

VOGT, U ;

HARMS, F ;

BOSSE, U ;

ZANKER, KS ;

ASSMANN, G .

GENE, 1995, 159 (01) :29-34

[7] PROGNOSTIC RELEVANCE OF ABERRATIONS IN THE ERBB ONCOGENES FROM BREAST, OVARIAN, ORAL AND LUNG CANCERS - DOUBLE-DIFFERENTIAL POLYMERASE CHAIN-REACTION (DDPCR) FOR CLINICAL-DIAGNOSIS [J].

BRANDT, B ;

VOGT, U ;

SCHLOTTER, CM ;

JACKISCH, C ;

WERKMEISTER, R ;

THOMAS, M ;

VONEIFF, M ;

BOSSE, U ;

ASSMANN, G ;

ZANKER, KS .

GENE, 1995, 159 (01) :35-42

[8] Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? [J].

Clark, GM .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1320-1321

[9] Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer [J].

Cortazar, P ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1625-1631

[10] Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity [J].

Cree, IA ;

Kurbacher, CM ;

Untch, M ;

Sutherland, LA ;

Hunter, EM ;

Subedi, AMC ;

James, EA ;

Dewar, JA ;

Preece, PE ;

Andreotti, PE ;

Bruckner, HW .

ANTI-CANCER DRUGS, 1996, 7 (06) :630-635

← 1 2 3 4 →